Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04447651 · ClinicalTrials.gov registry record
Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
A clinical trial of Metastatic Solid Tumor and SF3B1 Gene Mutation, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Active
- Registry status
- 6
- Enrollment target
- 1
- Study location
NCT04447651 is a study of Metastatic Solid Tumor and SF3B1 Gene Mutation that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 6 participants, below the 192-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04447651, a study of Metastatic Solid Tumor and SF3B1 Gene Mutation, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- ACTIVE NOT RECRUITING
- Registry status
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to see if patients with metastatic solid tumors (hematologic malignancies and lymphoma excluded) who have a specific genetic mutation in patients' tumor (the SF3B1, U2AF1 or SRSF2 mutation), are more likely to respond to immunotherapy agents that are now commercially available.
Conditions Studied
Interventions
- OTHER Recommendation for treatment with immunotherapy
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2026-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04447651
The ClinicalTrials.gov registry entry for NCT04447651 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target (97% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Metastatic Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Recommendation for treatment with immunotherapy is the first listed.
NCT04447651 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04447651 about?
NCT04447651 is a clinical study titled "Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)". This study is being done to see if patients with metastatic solid tumors (hematologic malignancies and lymphoma excluded) who have a specific genetic mutation in patients' tumor (the SF3B1, U2AF1 or SRSF2 mutation), are more likely to respond to immunotherapy agents that are now commercially availab...
What is the current status of trial NCT04447651?
This trial is currently active not recruiting. The enrollment target is 6 participants. The study started on 2020-09-17. Estimated completion is 2026-08.
What conditions does trial NCT04447651 study?
This clinical trial studies the following conditions: Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation, U2AF1 Gene Mutation, SRSF2 Gene Mutation.
What interventions are being tested in trial NCT04447651?
The interventions under investigation include: Recommendation for treatment with immunotherapy (OTHER).
Who is sponsoring clinical trial NCT04447651?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04447651 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
RECRUITING · Phase 1
-
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.